Previous studies have indicated many biomarkers considered as prognosticators, as well as indicators of screening and potential therapeutic targets for lung cancer, such as carcinoembryonic antigen, cytokeratin 19 fragment (CYFRA21-1), circulating cell free DNA, C-reactive protein, interleukin-6 (IL-6), and repetitive A (A type 3) [2–6]. This evidence concerns the gene IL6 and lung carcinoma.